Canatu licenses its CNT reactor to South Korea’s FST for chip-making pellicles, marking a key step in commercializing carbon nanotube tech.

Canatu has granted South Korea’s FINE SEMITECH CORPORATION a commercial license to use its CNT100 SEMI reactor for mass-producing carbon nanotube pellicle membranes, crucial for advanced chip manufacturing. The reactor, shipped in September 2024 and approved in July 2025, enables FST to begin production. Canatu received a one-time license fee in the lower half of the 1–5 million euro range, with revenue recognized in Q4 2025. Future income may come from sales of proprietary consumables and royalties on pellicles sold by FST, though these depend on FST’s success. The milestone underscores growing market demand for CNT pellicle technology.